• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Gastrointestinal Bleeding - Pipeline Review, H2 2012 Product Image

Gastrointestinal Bleeding - Pipeline Review, H2 2012

  • Published: December 2012
  • 42 pages
  • Global Markets Direct

Gastrointestinal Bleeding – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Gastrointestinal Bleeding - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gastrointestinal Bleeding, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastrointestinal Bleeding. Gastrointestinal Bleeding - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gastrointestinal Bleeding.
- A review of the Gastrointestinal Bleeding products under READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Gastrointestinal Bleeding Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Gastrointestinal Bleeding 7
Gastrointestinal Bleeding Therapeutics under Development by Companies 9
Gastrointestinal Bleeding Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Gastrointestinal Bleeding Therapeutics – Products under Development by Companies 14
Gastrointestinal Bleeding Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Gastrointestinal Bleeding Therapeutics Development 16
AstraZeneca PLC 16
Ocera Therapeutics, Inc. 17
Gastrointestinal Bleeding – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
esomeprazole magnesium - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ornithine phenylacetate - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
thalidomide - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
tranexamic acid - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ornithine phenylacetate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
octreotide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Gastrointestinal Bleeding Therapeutics – Drug Profile Updates 31
Gastrointestinal Bleeding Therapeutics – Discontinued Products 33
Gastrointestinal Bleeding Therapeutics - Dormant Products 34
Gastrointestinal Bleeding – Product Development Milestones 35
Featured News & Press Releases 35
May 29, 2012: Ocera Therapeutics Announces Preliminary Data From Phase II Study Of OCR-002 For Treatment Of Cirrhosis Of Liver And Upper GI Bleeding 35
Apr 01, 2010: Santarus Announces Launch of ZEGERID OTC by Schering-Plough Consumer HealthCare 36
Dec 22, 2009: Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC 36
Dec 01, 2009: Santarus Announces FDA Approval of Schering-Plough HealthCare Products' ZEGERID OTC 37
Oct 12, 2009: Santarus and Norgine Enter License for ZEGERID Immediate-Release Omeprazole Products in Europe 38
Jun 23, 2009: Santarus Announces December 2009 Action Date for Schering-Plough's OTC ZEGERID New Drug Application 38
Jun 09, 2009: Santarus Announces Schering-Plough Response Submission to FDA for OTC ZEGERID 39
Jun 01, 2009: Positive PK Data from Investigator-Initiated Pilot Study with ZEGERID to Be Presented in Poster Session at DDW 39
Jan 13, 2009: Santarus Announces Complete Response Letter from FDA on Schering-Plough's New Drug Application for OTC ZEGERID 39
Jul 08, 2008: Santarus Announces Issuance Date of Additional U.S. Patent Covering Zegerid Products 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Number of Products Under Development for Gastrointestinal Bleeding, H2 2012 7
Products under Development for Gastrointestinal Bleeding – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
AstraZeneca PLC, H2 2012 16
Ocera Therapeutics, Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Gastrointestinal Bleeding Therapeutics – Drug Profile Updates 31
Gastrointestinal Bleeding Therapeutics – Discontinued Products 33
Gastrointestinal Bleeding Therapeutics – Dormant Products 34

List of Figures
Number of Products under Development for Gastrointestinal Bleeding, H2 2012 7
Products under Development for Gastrointestinal Bleeding – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos